SEE FAR CBT Intervention for Adults With PTSD
ConditionPost Traumatic Stress Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCommunity Stress Prevention Center
About this trial
This single-arm clinical intervention study evaluates a 12-session SEE FAR CBT intervention for adults aged 18 years and older with posttraumatic stress disorder (PTSD). SEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will complete self-report psychological questionnaires at three time points: baseline, after completion of the intervention, and at a 3-month follow-up. The study aims to examine changes in PTSD symptoms and related psychological outcomes over the course of treatment and follow-up.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 years or older
PTSD symptoms, defined as a PCL-5 score of 30 or above
Able to provide informed consent
Willing and able to participate in 12 weekly individual therapy sessions and complete study questionnaires at baseline, post-intervention, and 3-month follow-up
Disqualifiers
Pregnancy at the time of enrollment, due to the potential influence of pregnancy and childbirth during the treatment or follow-up period on psychological outcomes.
Currently receiving psychotherapy of any type that began less than 3 months prior to enrolment.
Initiation of psychiatric medication less than 3 months prior to enrolment.
Trial design
Design model
Single group
Treatments tested in this trial
SEE FAR CBT
BehavioralSEE FAR CBT is a trauma-focused cognitive-behavioral treatment approach. Participants will receive 12 therapeutic sessions delivered approximately once weekly as a structured psychological intervention for PTSD.
Treatment groups
60 Participants
are divided into 1 treatment groupGroup A: SEE FAR CBT InterventionExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in PTSD symptoms
PTSD Checklist for DSM-5 (PCL-5). PTSD symptoms will be assessed using the PCL-5. Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. Change in PCL-5 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Time frame
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention2
Change in anxiety symptoms
Generalized Anxiety Disorder-7 (GAD-7). Anxiety symptoms will be assessed using the GAD-7. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity. Change in GAD-7 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Time frame
Baseline, 12-16 weeks after baseline, and 3 months after completion of the interventionSecondary outcomes
1
Change in depressive symptoms
Patient Health Questionnaire-9 (PHQ-9). Depressive symptoms will be assessed using the PHQ-9. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity. Change in PHQ-9 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Time frame
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention2
Change in perceived stress
Perceived Stress Scale (PSS). Perceived stress will be assessed using the PSS. Total scores range from 0 to 40, with higher scores indicating greater perceived stress. Change in PSS total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Time frame
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention3
Change in resilience
Connor-Davidson Resilience Scale (CD-RISC-10). Resilience will be assessed using the CD-RISC. Total scores range from 0 to 40, with higher scores indicating greater resilience. Change in CD-RISC total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Time frame
Baseline, 12-16 weeks after baseline, and 3 months after completion of the intervention4
Change in somatic symptoms
Patient Health Questionnaire-15 (PHQ-15). Somatic symptoms will be assessed using the PHQ-15. Total scores range from 0 to 30, with higher scores indicating greater somatic symptom severity. Change in PHQ-15 total score will be examined from baseline to post-intervention, from baseline to 3-month follow-up, and from post-intervention to 3-month follow-up.
Time frame
Baseline, 12-16 weeks after baseline, and 3 months after completion of the interventionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov